TRH-SR

Drug Profile

TRH-SR

Latest Information Update: 11 Oct 2000

Price : $50

At a glance

  • Originator Takeda
  • Class Hormones; Neuroprotectants; Nootropics
  • Mechanism of Action Thyrotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cognition disorders; Neurological disorders

Most Recent Events

  • 11 Oct 2000 Discontinued-Unspecified for Cognition disorders in Japan (SC)
  • 11 Oct 2000 Discontinued-Unspecified for Neurological disorders in Japan (SC)
  • 17 Jan 1997 No-Development-Reported for Neurological disorders in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top